Bausch + Lomb’s $ 630 million IPO was the biggest one in the second quarter of this year. It was also an outlier. The steep drop off in IPO activity continued in the most recent quarter, which saw the number of completed new stock offerings dip to levels last seen in the Great Recession of … Read more
Job turnover is on the rise among physicians because their desire for flexibility and work-life balance is emboldening them to leave jobs where they feel overworked or underappreciated, according to a new report released by healthcare staffing company CHG Healthcare. The report found that 43% of physicians switched jobs during the pandemic. It also found … Read more
Novartis is paying $ 100 million now for the opportunity to shorten the regulatory review of a rare disease drug candidates in the indeterminate future, a move that could save time and bring a potential blockbuster product to the market sooner, assuming it passes FDA muster. The Swiss pharmaceutical giant has reached a deal to … Read more
As inflation soars and pandemic-era aid comes to an end, many industries and Americans have been struggling to thrive in the post-pandemic economic landscape. The US healthcare system is no stranger to this victimhood – some of the nation’s largest health systems recorded substantial net losses in the first quarter of 2022. For example, Permanent … Read more
Biopharma companies may want to pause before they plow ahead with their next acquisition. The costs are rising and the potential returns are falling, according to a report published in late June by accounting and consulting firm Accenture. Other growth strategies, however, could prove more promising in the years ahead, noted the report, which predicts … Read more
Sanofi multiple sclerosis drug candidate tolebrutinib boasts a key feature: the ability to reach into brain and spinal cord tissue to provide its therapeutic effect. But liver problems have been reported in some patients dosed with the experimental treatment, leading the FDA to pause the drug’s pivotal clinical trials. According to Sanofi, the FDA based … Read more
As Pride Month comes to a close, it is important to remember that members of the LGBTQ community still experience significant health disparities compared to the general population in the US Research shows nearly one-sixth of LGBTQ Americans avoid or delay medical treatment because of discrimination, and about 30% find it difficult to access care … Read more
The issues of choice and motherhood have dominated headlines over the past week. This discourse has centered around a woman’s choice to have a child, but there is also a lesser-discussed maternal choice becoming eliminated for some women: the choice of how they will feed their newborn. The US has a severe lack of accessible … Read more
The federal government has reached a deal to pay $ 3.2 billion to secure a new supply of the Pfizer / BioNTech Covid-19 vaccine that includes shots specifically adapted to the omicron variant that is now dominant. The agreement announced late Wednesday covers the purchase of 105 million doses. The government also has the option … Read more
A recent webinar by Medable discussed steps it’s taking to improve clinical trial design through decentralized clinical trials (DCT). The Covid-19 public health crisis has accelerated the adoption of DCT. But life science companies are taking steps to do more to increase diversity in clinical trial recruitment. Part of that effort involves figuring out how … Read more